Mounjaro Long-Term Side Effects: What the Evidence Actually Shows

What do clinical trials actually tell us about long-term Mounjaro side effects?

The SURMOUNT-1 trial ran for 72 weeks and remains the most detailed window into how tirzepatide behaves over an extended period. Thousands of adults without diabetes participated, and the trial reported an average body-weight reduction of around 20–21% at the 15mg dose — but the side-effect data collected over those 72 weeks is equally instructive.

Gastrointestinal effects were the most common finding. Nausea topped the list, followed by diarrhoea, constipation, vomiting and indigestion. These effects were most pronounced during the starting weeks and after each dose step upward, then tended to subside. The trial did not find that GI effects accumulated or worsened the longer treatment continued at a stable dose, a reassurance worth noting, even if individual experience varies.

Injection-site reactions, fatigue, and headache were also reported but at lower rates. The NHS medicines page for tirzepatide sets out the full list of known effects from the approved SmPC, and it is worth reading before starting treatment. Our Mounjaro side effects overview covers the common and uncommon categories in plain language if you want a fuller breakdown.

One point the trials cannot yet fully answer: very long-term effects beyond two years remain under active study. This is precisely why Mounjaro holds Black Triangle status, the MHRA collects real-world pharmacovigilance data as the medicine's use widens.

Are there serious long-term risks that warrant closer attention?

Yes, and being honest about them matters. The risks below are not common, but they are real and some require prompt action.

Pancreatitis. In January 2026, the MHRA issued a Drug Safety Update specifically addressing acute pancreatitis as a known, infrequent but potentially serious effect of GLP-1 medicines including tirzepatide. The symptom to take seriously is severe, persistent stomach pain, particularly pain that spreads toward the back, with or without vomiting. If that happens, stop treatment and get urgent medical help the same day.

Gallbladder problems. Rapid weight loss of any kind can increase the risk of gallstones and cholecystitis. This risk is not unique to Mounjaro but is worth monitoring, especially in those with a prior gallbladder history.

Thyroid considerations. Animal studies raised a theoretical concern about thyroid C-cell tumours. No causal link has been established in humans, but Mounjaro is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). A prescriber will ask about this before treatment.

For more on questions the data has not yet fully settled, our page on whether Mounjaro is safe long term works through the evidence honestly. The cancer question specifically is addressed on our Mounjaro long-term cancer risk page.

When should someone on Mounjaro get medical help immediately?

This matters more than any other section on this page, so it is stated plainly.

Call 111 or go to A&E for: severe abdominal pain that is persistent or radiating to the back (possible pancreatitis); signs of a serious allergic reaction, swelling of the face, lips or throat, difficulty breathing, or a rapid heart rate; severe vomiting or diarrhoea leading to dehydration (you cannot keep fluids down); or any signs of acute kidney problems such as passing very little urine alongside confusion or severe fatigue.

Contact your prescriber or GP soon (not immediately, but don't leave it) for: a new or worsening low mood or thoughts about self-harm; upper right abdominal pain that could suggest gallbladder problems; unexplained lump in the neck; or any new symptom that concerns you and does not resolve after a few days.

The long-term side effects of Mounjaro page goes into greater clinical depth for readers who want referenced detail on each category. If you have a specific concern mid-treatment, our aftercare team is available seven days a week.

How does long-term side-effect monitoring work in practice?

Clinical review does not end at the first prescription. For any responsible prescribing service, each repeat order is a checkpoint, weight is re-verified, any new symptoms or medicines are reviewed, and suitability for continuing is confirmed fresh rather than assumed.

At the population level, Mounjaro's Black Triangle status means every prescriber and pharmacist is expected to report suspected adverse reactions. The Yellow Card scheme, run by the MHRA, collects this data continuously; patients can self-report too, directly at yellowcard.mhra.gov.uk. That ongoing signal is how post-market safety guidance evolves, the January 2026 pancreatitis Drug Safety Update is a direct example of the system working as intended.

If you are considering treatment and want to understand how the side-effect and monitoring conversation happens in practice, the clinical evidence on Mounjaro's long-term profile is worth reading alongside this page. Our prescribers discuss suitability and the full side-effect picture as a standard part of every consultation, the treatment page is the right place to start that conversation. When your pen eventually arrives (tracked with DPD in plain, unbranded packaging) the Patient Information Leaflet inside is the authoritative reference for what to do if a side effect troubles you.

For a broader overview of the medicine itself, our Mounjaro guide covers how it works, who it is licensed for, and what the treatment pathway looks like.